Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Clinical trial NCT06577441 · RECRUITING
Trial details
- NCT number
- NCT06577441
- Sponsor
- National Cancer Institute (NCI)
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-12
- Primary completion
- 2027-03-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.